http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100455900-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D303-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 |
| filingDate | 2001-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2004-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100455900-B1 |
| titleOfInvention | Novel fumagillol derivatives and preparing method thereof |
| abstract | The present invention relates to a fumarylol derivative represented by the following formula (1) and a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition comprising the same. Specifically, the fumarylol derivative of the present invention represented by the following formula (1) After acylating the fumarylol, it is prepared by performing a substitution reaction with an aromatic derivative including various functional groups and an additional oxirane ring-opening reaction, and has excellent anti-angiogenic effect and low toxicity, and thus anticancer agent, cancer metastasis inhibitor, rheumatoid arthritis treatment agent , Psoriasis or diabetic retinopathy can be usefully used.n n n Formula 1n n n n n n n n (Wherein B, R 1 , R 2 , R 3 , R 4 , R 5 , X, Y, Z 1 , Z 2 , Z 3 and Z 4 are as defined in the specification.) |
| priorityDate | 2001-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 170.